Previous Close | 7.91 |
Open | 7.62 |
Bid | 7.40 x 800 |
Ask | 7.41 x 900 |
Day's Range | 7.24 - 7.70 |
52 Week Range | 7.24 - 19.32 |
Volume | |
Avg. Volume | 889,400 |
Market Cap | 576.801M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.75 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for CHRS
- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O’Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Boa
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ETUBS Global Healthcare Conference on Tuesday, May 24 at 2:00 p.m. ETH.C. Wainwright Global Investment Conference on Wednesday, May 25 at 9:00 a.m. ET Audio webcasts of these presentations will be available on the inve